Investigators showed that concurrent ASXL1 and NRAS mutations defined a population of chronic myelomonocytic leukemia patients with shorter leukemia-free survival than those with ASXL1 mutation only.
[Blood]
7992332
BBBBBBBB
items
1
apa
0
default
asc
1
168481
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
